Andrographis Research: Cell, Animal, and Human Evidence Compared

Andrographis Research: Cell, Animal, and Human Evidence Compared

Andrographis paniculata—a bitter-tasting herb long used in South and Southeast Asian traditional medicine—has attracted a substantial body of laboratory research examining its constituent compounds, chiefly andrographolide and related diterpene lactones. The published literature spans cell-culture experiments, rodent models, and a smaller number of human clinical investigations. These categories of evidence are not interchangeable, and much of the confusion around Andrographis stems from treating findings from one category as if they applied to another. This article separates what has actually been studied, in what system, and what that does and does not support.

Identity and form

Andrographis paniculata preparations used in research vary considerably. Some studies use crude ethanolic or methanolic extracts of the aerial parts or whole plant; others use solvent-partitioned fractions (dichloromethane, petroleum ether, ethyl acetate, aqueous); and still others use isolated, purified andrographolide or related diterpenes such as 14-deoxyandrographolide and 14-deoxy-11,12-didehydroandrographolide [PMID: 15138014]. These are materially different substances. A crude ethanol extract contains a mixture of compounds that may act together, while purified andrographolide is a single molecule tested in isolation. Research comparing these forms directly has found that they do not always behave the same way—one study reported that a crude ethanol extract produced stronger immune-related effects in mice than purified andrographolide did, suggesting other constituents in the extract contributed to the response [PMID: 8377022]. Because of this, a finding generated with one fraction or isolate cannot be assumed to apply to a different preparation, a different extraction ratio, or a whole-herb powder. When comparing studies, the specific form used—crude extract, solvent fraction, or isolated compound—is one of the most important variables to track, alongside the standardization or marker-compound amount, since these details determine whether results are even comparable to one another, let alone to a finished consumer product.

In vitro (cell-culture) evidence

The largest share of Andrographis research by volume is in vitro—that is, conducted in isolated cells or cell lines outside a living organism. This category includes work on cancer cell lines and on immune cells drawn from human blood.

One frequently cited study fractionated a methanolic extract and tested the resulting fractions on human colon cancer cells (HT-29) and human peripheral blood lymphocytes (HPBLs). The dichloromethane fraction inhibited proliferation of the cancer cell line while, at low concentrations, increasing proliferation of the lymphocytes; three isolated diterpenes—andrographolide, 14-deoxyandrographolide, and 14-deoxy-11,12-didehydroandrographolide—each increased lymphocyte proliferation and interleukin-2 (IL-2) production in this cell-culture system [PMID: 15138014]. A related study by an overlapping research group examined andrographolide's action on human cancer and immune cells directly, reporting that it arrested certain cancer cell lines in the G0/G1 phase of the cell cycle through changes in specific regulatory proteins, while separately increasing lymphocyte proliferation, IL-2 production, tumor necrosis factor-alpha output, and cytotoxic activity against cancer cells in culture [PMID: 14641821].

Other in vitro work has focused on inflammatory signaling rather than cancer cells. In mouse macrophage cultures (the RAW 264.7 cell line) stimulated with bacterial endotoxin and interferon-gamma, andrographolide reduced nitric oxide production in a dose-dependent manner, apparently by lowering the amount of inducible nitric oxide synthase (iNOS) protein through effects on protein synthesis and stability rather than by changing the corresponding gene's mRNA output [PMID: 10780958]. A separate study using mouse peritoneal macrophages found that an ethyl acetate fraction of Andrographis paniculata reduced NF-kappaB signaling activity along with secretion of nitric oxide and prostaglandin E2 in cells stimulated with endotoxin and interferon-gamma—but the same fraction had no measurable effect on interferon-gamma production in a different immune-cell population (mouse splenocytes) activated with a plant lectin, illustrating that effects observed in one cell type under one stimulation protocol do not necessarily generalize even within the same broad category of immune cell [PMID: 19111919].

Additional in vitro research has examined andrographolide's effects on lymphoma cell lines and primary patient-derived tumor cells, reporting that the compound triggered a form of programmed cell death (apoptosis) linked to oxidative stress and mitochondrial pathways, an effect that could be blocked by an antioxidant and enhanced by a glutathione-depleting agent in the culture system [PMID: 20798229]. In non-small-cell lung cancer cell lines and xenograft-bearing mice, andrographolide was reported to reduce expression of the PD-L1 protein by interfering with JAK2/STAT3 signaling and to promote a selective autophagic degradation pathway, with the combination of andrographolide and an anti-PD-1 antibody outperforming either treatment alone in the mouse xenograft model [PMID: 35367343]. These are laboratory and animal-model findings relevant to basic cancer biology research; they do not constitute evidence of benefit in humans and do not describe a structure/function outcome relevant to a dietary ingredient.

Taken together, in vitro findings establish plausible biological mechanisms—effects on cell-cycle regulators, cytokine output, nitric oxide synthesis, and signaling pathways such as NF-kappaB and JAK2/STAT3. They cannot establish that these mechanisms occur, at similar magnitude, in an intact human body, where absorption, metabolism, dose reaching target tissue, and countless other variables differ enormously from a culture dish.

Animal evidence

A smaller set of studies moves from isolated cells to whole animals, typically mice. One early study administered an ethanol extract and purified andrographolide to mice and measured antibody responses and delayed-type hypersensitivity to sheep red blood cells, along with macrophage migration and phagocytosis of labeled bacteria. Both the extract and the purified compound stimulated these measures of immune activity, but the ethanol extract produced a stronger effect than andrographolide alone, again pointing to a contribution from other constituents in the whole extract [PMID: 8377022].

Another animal study examined andrographolide's effect on T-cell activation and on a mouse model of experimental autoimmune encephalomyelitis (EAE), a model used to study autoimmune inflammation of the central nervous system. Researchers reported that andrographolide interfered with T-cell proliferation and cytokine release in vitro, blocked dendritic cell maturation and antigen presentation, and reduced antibody and delayed-type hypersensitivity responses in living mice; treated mice also showed fewer EAE symptoms [PMID: 15331658]. This is a disease-model finding in mice and describes a suppressive, not stimulatory, direction of immune modulation—an important distinction, since some in vitro work reports stimulatory effects on lymphocyte proliferation while this animal study reports the opposite direction of effect on T-cell activation. The discrepancy likely reflects differences in cell type, dose, timing, and the specific immune pathway measured, and it is a clear illustration of why isolated findings should not be extrapolated into a single narrative about "immune support."

A separate line of animal research, conducted in poultry rather than mammals, tested a fermented combination product containing Andrographis paniculata alongside four other Chinese herbs and two probiotic bacterial strains in broiler chickens. Compared to several control groups, the combination preparation was associated with greater body weight gain, improved feed efficiency, higher secretory immunoglobulin A and glutathione peroxidase levels, larger intestinal villus height, and increased expression of two intestinal barrier-related genes [PMID: 34920387]. This is livestock research using a multi-ingredient fermented product, not an isolated Andrographis extract, and the outcomes (growth performance, feed conversion) are agricultural production metrics that do not translate into human dietary outcomes. It cannot be used to infer anything about digestive or immune effects of Andrographis alone in humans.

Human evidence

Human clinical evidence on Andrographis paniculata is considerably more limited than the in vitro and animal literature, and much of what exists is embedded in broader reviews rather than dedicated large trials on the herb by itself. A review of herbal therapies in inflammatory bowel disease noted that an Andrographis paniculata extract was among several botanicals reported to be superior to placebo in inducing remission or clinical response in ulcerative colitis, alongside separate trials of aloe vera gel and other plant preparations [PMID: 25830661]. This review explicitly characterized the overall body of herbal IBD evidence as based on a relatively small number of clinical studies and called for larger, double-blind trials before firmer conclusions could be drawn. Because this is a secondary review summarizing multiple herbs and multiple trials rather than a full description of one dedicated Andrographis-only trial, the details of population size, dose, extract standardization, and trial duration are not specified in the material available here, which limits how much weight this single data point can carry.

Broader review literature on "heat-clearing" Chinese herbs, of which Andrographis paniculata is one example among eleven discussed, describes reported anti-inflammatory and antimicrobial mechanisms across this class of botanicals but explicitly frames the field as needing further study to clarify detailed mechanisms of action [PMID: 24860732]. A separate systematic review focused specifically on andrographolide's role in cancer research reported that, among 139 included studies, the overwhelming majority (109) were non-clinical laboratory work, with only three preclinical, three clinical, and three non-preclinical trials identified in total—a distribution that itself demonstrates how disproportionately small the human clinical evidence base is relative to laboratory research on this compound [PMID: 29408515]. That review's own authors framed andrographolide as a candidate worth continued investigation rather than a settled clinical tool, and its scope was oncology research, not general immune or digestive structure/function outcomes.

Comparing the evidence types side by side

Laid out together, the picture is one of a steep pyramid: a wide base of in vitro mechanistic work, a narrower middle layer of animal studies (mostly in mice, with one poultry study using a multi-herb combination product), and a very thin top layer of human clinical evidence, much of it embedded within reviews covering multiple herbs rather than dedicated Andrographis trials. The mechanistic consistency across cell and animal studies—effects on NF-kappaB signaling, nitric oxide production, T-cell activation, and cytokine release—is notable and suggests plausible biological activity worth continued investigation. But consistency at the mechanistic level is not the same as demonstrated benefit in humans. Extract form also varies so widely across studies (crude ethanol or methanol extracts, solvent fractions, purified andrographolide, fermented multi-herb combinations) that even the mechanistic literature does not point to one clearly superior form; different fractions and isolates produced different magnitudes and sometimes different directions of effect within the same broad research program [PMID: 15138014] [PMID: 8377022].

What the evidence does not show

This body of research does not establish that Andrographis paniculata, in any commercially available form, treats, prevents, or cures any disease, including cancer, autoimmune conditions, or inflammatory bowel disease. Cell-culture findings on cancer cell lines and cytokine production describe laboratory observations under controlled, artificial conditions and cannot be read as evidence of anticancer or immune benefit in humans. Animal findings, including the EAE mouse model and the broiler chicken production study, describe outcomes in non-human systems using doses, routes, and endpoints that do not directly map onto human dietary use. The single human IBD review citation describes a modest, review-level summary of a small clinical literature, explicitly flagged by its own authors as needing larger, better-controlled trials, and it concerns a specific diagnosed digestive condition rather than general digestive function in healthy people. No source in this packet reports a randomized controlled trial of an isolated Andrographis extract on immune function outcomes in healthy human volunteers. Where cell and animal studies disagree on the direction of immune effect—some reporting stimulation of lymphocyte activity, another reporting suppression of T-cell activation—the evidence does not currently resolve which effect, if any, predominates in an intact human immune system. None of this research validates any specific commercial extract, dose, or finished formulation, and identity, sourcing, and standardization details differ enough across studies that findings from one preparation should not be assumed to apply to another.

Safety and decision context

Safety data specific to long-term human use, drug interactions, and use during pregnancy or breastfeeding are not detailed in the research packet reviewed here beyond the general caution that pregnancy and breastfeeding safety for Andrographis is uncertain and warrants specific caution. Anyone considering Andrographis in any form—particularly during pregnancy or breastfeeding, alongside prescription medication, or with an existing diagnosed condition—should review their complete health history, current medications, and the full label of any product with a qualified healthcare professional before use.

Limits of the evidence

The research summarized above spans in vitro cell studies, mouse and poultry animal models, and a small number of human-relevant review citations. Findings from one category cannot be assumed to transfer to another: a mechanism identified in a macrophage cell line does not confirm an effect in living tissue, and an effect in mice does not confirm the same effect, at a comparable dose, in humans. Extract form, fractionation method, and whether a study used a crude extract versus an isolated compound versus a multi-ingredient fermented product are all variables that materially change what a given result can support. Several of the animal and cell studies used doses or concentrations not directly comparable to typical human dietary intake. The human evidence available in this packet is drawn largely from review articles summarizing multiple herbs and multiple small trials rather than from large, dedicated, placebo-controlled trials of a single standardized Andrographis extract, and the reviewing authors themselves called for further controlled human research. No source here supports a disease treatment, prevention, or cure claim, and none of this research should be read as validating any specific commercial product, dose, or formulation.

Selected sources

• Anticancer and immunostimulatory compounds from Andrographis paniculata [PMID: 15138014]
• Immunostimulant agents from Andrographis paniculata [PMID: 8377022]
• Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata [PMID: 14641821]
• Anti-inflammatory and Antimicrobial Effects of Heat-Clearing Chinese Herbs: A Current Review [PMID: 24860732]
• Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer [PMID: 29408515]
• Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide [PMID: 10780958]
• Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse [PMID: 15331658]
• Herbal and plant therapy in patients with inflammatory bowel disease [PMID: 25830661]
• Mitochondrial-mediated apoptosis in lymphoma cells by andrographolide [PMID: 20798229]
• Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response [PMID: 35367343]
• The production of nitric oxide and prostaglandin E2 in peritoneal macrophages is inhibited by Andrographis paniculata, Angelica sinensis and Morus alba ethyl acetate fractions [PMID: 19111919]
• Effects of novel microecologics combined with traditional Chinese medicine and probiotics on growth performance and health of broilers [PMID: 34920387]

Editorial note

This article was prepared by WQ's science editorial desk as an educational comparison of research evidence categories for Andrographis paniculata. It draws exclusively on the peer-reviewed and review literature cited above and does not reference or recommend any WQ product or formulation. High-risk topics referenced here, including pregnancy and breastfeeding, are presented for educational awareness only and were subject to manual editorial review.

This article is for educational purposes only and has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease.